Financial Disclosure Guidance Should Put Less Burden On Sponsors - HIMA
This article was originally published in The Gray Sheet
Executive Summary
FDA should revise its draft guidance on financial disclosures by clinical investigators to ensure that clinical data is not rejected if a sponsor is unable to obtain financial information from foreign investigators, the Health Industry Manufacturers Association contends in Dec. 23 comments to the agency.